1.. Introduction {#s0001}
================

Coronaviruses are a large virus's family that causes illnesses ranging from a common cold (some seasonal viruses are coronaviruses) to more severe conditions such as SARS-CoV or Mers-CoV (Jabeer Khan et al., [@CIT0029]; Enayatkhani et al., [@CIT0019]; Elfiky & Azzam, [@CIT0017]). This virus is from the family Coronaviridae and was detected in the city of Wuhan in China (Khan et al., [@CIT0032]; Elmezayen et al., [@CIT0018]). It was originally named 2019-nCoV. It is now called SARS-CoV-2 (Pant et al., [@CIT0043]). The disease associated with this virus is COVID-19. The onset of the COVID-19 atypical pneumonia outbreak was reported on December 31, 2019 (Sarma et al., [@CIT0050]; Gupta et al., [@CIT0023]). Common symptoms include fever, cough, and shortness of breath . Other symptoms may include fatigue, muscle pain, diarrhea, sore throat, loss of smell, and abdominal pain (Hopkins, [@CIT0026]). The time from exposure to onset of symptoms is typically around five days but may range from two to fourteen days (Velavan & Meyer, [@CIT0060]). While the majority of cases result in mild symptoms, some progress to viral pneumonia and multi-organ failure (Hui et al., [@CIT0027]; Muralidharan et al., [@CIT0041]). As of 16 April 2020, more than 2.13 million cases have been reported across 210 countries and territories, resulting in more than 142,000 deaths. More than 540,000 people have recovered.

Coronaviruses have in common proteins designated by a letter indicating their location: S (protuberances), E (envelope), M (membrane) and N (nucleocapsid). Some, in particular those of subgroup A of the genus Betacoronavirus, have a characteristic HE protein (hemagglutinin esterase). The SARS coronavirus also presents on protein S a specific binding site for the angiotensin converting enzyme 2 (ACE2) which serves as an entry point into the host cell (Fang, 2005). Research suggests that the receptor is another potential target for vaccines or therapies. An inhibitor that blocks the receptor could make it more difficult for coronavirus to enter cells, which could at least significantly slow the epidemic until the virus disappears (Boopathy et al., [@CIT0009]; Hasan et al., [@CIT0024]).

Hence the interest of our study which consists in studying *in silico* the inhibition of ACE 2 by molecules derived from the essential oil of a medicinal plant which bears the name *Ammoides verticillata* (Desf.) Briq. This plant, is an aromatic plant widely used in western Algeria for its culinary and therapeutic purposes, it has proven antioxidant and antimicrobial activities of essential oil (Bekhechia et al., [@CIT0007]). The different names of *Ammoides verticillata* (Desf.) Briq. are French name Ajowan (Bekhechia et al., [@CIT0007]), Arabic name Nounkha Taleb El Koubs (Narayana et al., [@CIT0042]), Nûnkha (Trabut, [@CIT0057]; Abdelouahid & Bekhechi, [@CIT0002]). According to (Quezel & Santa, [@CIT0046]), this species is an annual herb that grows spontaneously in the matorrals of the western region of Algeria. This thread-like Apiaceae, with branched stems of 10--40 cm, without rosette of basal leaves. Lower petiolate leaves have many whorled multifide segments, upper pennatifides have linear segments. The main umbels are 8 - 15 rays. Ovoid fruit is less than 1 mm long [Figure 1](#F0001){ref-type="fig"}. It is generally found in fields, lawns, mountains and forests.

![*Ammoides verticillata* (Desf.) Briq from western Algeria.](TBSD_A_1763199_F0001_C){#F0001}

Studies have shown that the essential oil of *Ammoides verticillata* has very good antimicrobial activity against five bacterial strains (*Bacillus cereus*, *Staphylococcus aureus*, *Escherichia coli*, *Listeria monocytogenes* and *Micrococcus luteus*) and the yeast Candida albicans, with CIM values between 0.78 and 2.34 μl/ml. In addition, the essential oil can trap 50% of the free DPPH radical at a concentration of 15.37 μg/ml (Sandberg & Corrigon, [@CIT0048]; Higley & Higley, [@CIT0025]; Pole, [@CIT0044]). Also other study show that aerial parts (leaves and flowers) of *Ammoides verticillata* (Desf.) Briq. collected in occidental Algeria areas, exhibited a very unusual composition. Isothymol was by far the major component (51.2%), accompanied by p-cymene (14.1%), thymol (13.0%), limonene (11.9%) and γ- terpinene (6.8%) 11 (Kambouche & El-Abed, [@CIT0031]). According to (Lawrence, [@CIT0034]), it is worth noting that this oil is the richest source of naturally occurring isothymol (Bekhechia et al., [@CIT0007]). The aims of this study consist to establish a structure--activity relationship of actives principles of *Ammoides verticillata* compounds: Isothymol, Thymol, Limonene, P-Cymene and γ-Terpinene against ACE 2 activity compared to β-D- Mannose, co-cristallized inhibitor of this enzyme, this molecule is used in the RCSB data bank to block the ACE2 enzyme activity, and we compared also our results with 2 drugs which are used as good inhibitors to ACE2, the Captopril hypertension drug and Chloroquine antimalarials and amebicides drug which has also previously shown activity on coronavirus replication (Guastalegname & Vallone, [@CIT0022]). In this work we will take it as a witness for the discussion of our results to lead to other inhibitors which can also block the ACE2 enzyme activity and used as potential treatment of COVID-19. For this purpose, a molecular docking study was applied for testing the type of interactions between active site residues and the principles actives compounds from *Ammoides vericillata* with ACE2, and calculation of the binding free energies (S-score, kcal/mol) and bonds in order to predict the binding model of the selected compound to the three-dimensional structure of the enzyme (Aanouz et al., [@CIT0001]).

2.. Material and methods {#s0002}
========================

2.1.. Ligands and protein preparation {#s0003}
-------------------------------------

The three-dimensional (3 D) structures of compounds [Table 1](#t0001){ref-type="table"} were pre-optimized by means of the Molecular Mechanics Force Field (MM+). After that, the resulted minimized structures were further refined using the semi-empirical AM1 (Stewart, [@CIT0055]) with the Polak-Ribiere conjugate gradient algorithm of 0.01 kcal/(Åmol). All methods are implemented in Hyperchem 8.0.8 software (HyperChem v8, [@CIT0028]), a database was created in which all the ligands were converted into their 3 D structures and was used as input MOE-docking.

###### 

2 D&3D representations of the all ligands used in the experiment. The ligands structures were taken from PubChem server ([www.pubchem.ncbi.nlm.nih.gov](http://www.pubchem.ncbi.nlm.nih.gov)).

  Compound name                                 2D Structure                        3D Structure
  --------------------------------------------- ----------------------------------- -----------------------------------
  Isothymol                                     ![](TBSD_A_1763199_ILG0001_B.gif)   ![](TBSD_A_1763199_ILG0002_C.gif)
  p-cymene                                      ![](TBSD_A_1763199_ILG0003_B.gif)   ![](TBSD_A_1763199_ILG0004_B.gif)
  **Thymol**                                    ![](TBSD_A_1763199_ILG0005_B.gif)   ![](TBSD_A_1763199_ILG0006_C.gif)
  limonene                                      ![](TBSD_A_1763199_ILG0007_B.gif)   ![](TBSD_A_1763199_ILG0008_B.gif)
  γ-terpinene                                   ![](TBSD_A_1763199_ILG0009_B.gif)   ![](TBSD_A_1763199_ILG0010_C.gif)
  **beta-D-Mannose** (Co-cristallized ligand)   ![](TBSD_A_1763199_ILG0011_B.gif)   ![](TBSD_A_1763199_ILG0012_C.gif)
  Captopril                                     ![](TBSD_A_1763199_ILG0013_B.gif)   ![](TBSD_A_1763199_ILG0014_C.gif)
  Chloroquine                                   ![](TBSD_A_1763199_ILG0015_B.gif)   ![](TBSD_A_1763199_ILG0016_C.gif)

The X-ray crystal co-ordinates of ACE 2 (PDB ID: 6vw1) (Shang et al., [@CIT0052]) in the bound state with β-D- Mannose (formula: C~6~H~12~O~6~) [Table 2](#t0002){ref-type="table"}, were retrieved from RCSB Database (<http://www.rcsb.org/pdb>) [Figures 2](#F0002){ref-type="fig"} and [3](#F0003){ref-type="fig"}. This is selected for modeling studies. In the last, the energy of the proteins structures is minimized using the Energy minimization algorithm of MOE tool. These energy of proteins are calculated (in kcal/mol) by MOE using MMFF94x force field with conjugant gradient method.

![3 D structure of 2019-nCoV chimeric receptor-binding domain complexed with its receptor human ACE2 enzyme (PDB ID: 6vw1). The structure was taken from Protein Data Bank online server (<https://www.rcsb.org/>) and *Molecular Operating Environment* (MOE).](TBSD_A_1763199_F0002_C){#F0002}

![3 D structure of active site enzyme.](TBSD_A_1763199_F0003_C){#F0003}

###### 

Details related to the ACE2.

  Proteins               Methods             Resolution (Å)   R-Value   Residues number   Co-crystallized ligand   Docking Score Kcal/mol
  ---------------------- ------------------- ---------------- --------- ----------------- ------------------------ ------------------------
  **ACE2** PDB ID:6vw1   X-ray diffraction   2.68             0.229     597               β-D-Mannose              −5.4107

2.2.. Molecular docking protocol {#s0004}
--------------------------------

Docking calculations were carried out using standard default parameter settings in the MOE software package (*Molecular Operating Environment (MOE),),* [@CIT0039]). In this molecular docking program, the flexibility of ligands is considered while the proteins are considered as a rigid structure. In this case β-D- Mannose is first re-docked into the binding site pocket of ACE2 enzyme, and the root-mean-square deviation (RMSD) values between the docking and initial poses were calculated. In general, the protein structure with a resolution between 1.5 and 2.5 Å have a good quality for further studies (Clément & Slenzka, [@CIT0011]; Didierjean & Tête-Favier, [@CIT0013]), whereas, the resolution value of ACE2 not far to this interval. At the end of molecular docking, the best conformations of the ligands were analyzed for their binding interactions and were evaluated by the binding free energies (S-score, kcal/mol) and bonds interactions between ligand atom and active site residues.

2.3.. Ligand based druglikeness, ADME/toxicity properties and PASS prediction {#s0005}
-----------------------------------------------------------------------------

Many potential therapeutic agents fail to reach the clinic trials because of their unfavorable absorption, distribution, metabolism, and elimination (ADME) parameters; also it is not checking the druglikeness. Lipinski's rule of five (Lipinski et al., [@CIT0036]) Veber's rule (Veber et al., [@CIT0059]), Egan's rule (Veber et al., 2000) and Polar surface area (TPSA), number of rotatable (Daina et al., [@CIT0012]), the ADME/Toxicity (pharmacological and pharmacodynamic) properties, the PASS prediction, the P450 Site of Metabolism (SOM) and the Molecular Target studies were calculated using respectively SwissADME properties calculation online, PASS-Way2Drug server, RS-WebPredictor 1.0 and swiss target prediction.

2.4.. Phamacophore mapping {#s0006}
--------------------------

A pharmacophore consists of a pharmacologically active part of a molecule serving as a model. Pharmacophores are therefore sets of active atoms used in the design of drugs. The pharmacophore is an idealized geometric representation, only 3 D modeling can allow optimal use for the creation of new drugs.

A pharmacophore is the set of functional groups arranged in an adequate spatial arrangement, ensuring the fixation of the drug on the receptor and therefore capable of inducing the physiological response.

In this study the Phamacophore Mapping is carried for the Isothymol the best ligand among the selected ligands out using MOE software package (*Molecular Operating Environment (MOE),),* 2013).

2.5.. Molecular dynamics simulation {#s0007}
-----------------------------------

The molecular dynamics simulation study was carried out for the ligand that was declared as the best among the selected molecules. From the analysis of the results, it was declared that, Isothymol was the best ligand among the selected ligand molecules. The molecular dynamics simulation study of Isothymol and ACE2 docked complex was performed by iMODS. It is a fast, user-friendly and effective molecular dynamics simulation tool that can be used efficiently to investigate the structural dynamics of the protein complexes. It provides the values of deformability, B-factor (mobility profiles), eigenvalues, variance, co-varience map and elastic network. For a complex or protein, the deformability depends on the ability to deform at each of its amino acid residues. The eigenvalue has relation with the energy that is required to deform the given structure and the lower the eigenvalue, the easier the deformability of the complex.

Moreover, the eigenvalue also represents the motion stiffness of the protein complex. IMODS is a fast and easy server for determining and measuring the protein flexibility (Awan et al., [@CIT0005]; Prabhakar et al., [@CIT0045]; López-Blanco et al., [@CIT0037]; Lopéz-Blanco et al., [@CIT0038])

3.. Results and discussion {#s0008}
==========================

3.1.. Molecular docking simulation {#s0009}
----------------------------------

### 3.1.1.. The binding affinities of the ligands into ACE2 active site {#s0010}

The results calculations docking details received after dock all ligands with ACE2 target are listed in the [Table 3](#t0003){ref-type="table"}.

###### 

The docking results (binding energy) of all ligands and the controls along their respective number of hydrogen bonds as well as interacting amino acids.

  Names of ligands                             SP Docking Score (Binding Energy) (Kcal/mol)   Interacting residues of the target                                          Types of bonds                                  Distance (Å)               Energies (kcal-mol)
  -------------------------------------------- ---------------------------------------------- --------------------------------------------------------------------------- ----------------------------------------------- -------------------------- -------------------------------
  Chloroquine                                  −6.4530                                        OE1-GLU402 OE1-GLU406                                                       **H-donorIonic**                                **3.422.86**               **-1.0-5.5**
  Isothymol                                    −5.7853                                        6-ring-THR445                                                               **Pi-H**                                        **4.06**                   **-0.6**
  beta-D-Mannose (Co-cristallisation ligand)   −5.4107                                        O3-OE2 GLU 406 O4-OE2 GLU 406 O5-OE1 GLN 442 O5-NE2 GLN 442 O6-NZ LYS 441   **H-donorH-donorH-donorH-acceptorH-acceptor**   **2.992.942.903.083.15**   **-2.5  − 1.0  − 1.20.3-2.7**
  Captopril                                    −5.2248                                        NZ-LYS 441                                                                  **Ionic**                                       **3.12**                   **-1.0**
  Thymol                                       −4.7450                                        O1-OE1 GLU 406 6-ring- CG2 THR445                                           **H-donorPi-H**                                 **3.174.33**               **-3.0-0.9**
  limonene                                     −4.4067                                        /                                                                           **/**                                           **/**                      **/**
  p-cymene                                     −4.3630                                        /                                                                           **/**                                           **/**                      **/**
  γ-terpinene                                  −4.2320                                        /                                                                           **/**                                           **/**                      **/**

The molecules that had the lowest binding energy of docking score were considered the best molecule and inhibiting the target receptor as the lower binding energy corresponds to higher binding affinity (Simon et al., [@CIT0053]).

The ACE2-ligands complexes formed are shown in [Figure 4](#F0004){ref-type="fig"}.

![3 D representations of the best pose interactions between the ligands and their receptor. A. interaction between β-D-Mannose Co-cristallized ligand) and ACE2, B. interaction between Isothymol and ACE2, C. interaction between limonene and ACE2, D. interaction between p-cymene and ACE2, E. interaction between γ-terpinene and ACE2,F. interaction between Thymol and ACE2, G. interaction between Chloroquine and ACE2, H. interaction between Captopril and ACE2. The 3 D representations of the best pose interactions between the ligands and their respective receptors were visualized using *Molecular Operating Environment* (MOE).](TBSD_A_1763199_F0004_C){#F0004}

The binding mode observed for all ligands with pocket of receptor is represented in the [Figure 5](#F0005){ref-type="fig"}.

![2 D representations of the best pose interactions between the ligands and their receptor. A. interaction between β-D-Mannose (Co-cristallized ligand) and ACE2, B. interaction between Isothymol and ACE2, C. interaction between limonene and ACE2, D. interaction between p-cymene and ACE2, E. interaction between γ-terpinene and ACE2,F. interaction between Thymol and ACE2, G. interaction between Chloroquine and ACE2, H. interaction between Captopril and ACE2. The 2 D representations of the best pose interactions between the ligands and their respective receptors were visualized using *Molecular Operating Environment* (MOE).](TBSD_A_1763199_F0005_C){#F0005}

The Isothymol present score with -5.7853 Kcal/mol value and one hydrogen interaction with THR445 amino acids of 6vw1 target active site, the score β-D- Mannose (Co-crystallized ligand) is -5. 4107 Kcal/mol, 5 interactions with GLU406, GLU406, GLN442, GLN442, LYS441 residues target active site, the Thymol has -4, 7450 Kcal/mol, 2 interactions with GLU406 and THR445, the score values for the Limonene, P-Cymene and γ-Terpinene are respectively -4.4067, −4. 3630, −4. 2320 Kcal/mol and they have none interactions with residues target, Chloroquine has -6.4530 Kcal/mol score value, 2 interactions with OE1-GLU402 and OE1-GLU406 amino acids target and Captopril present -5.2248 Kcal/mol, one interaction with NZ-LYS 441 residues of 6vw1 target. We compared all the values score complexes; we found that complex formed by 6vw1-Isothymol has the lowest value energy and giving the best docking score compared to β-D- Mannose co-crystallized inhibitor and Captopril. On the other hand Isothymol has a lower molecular weight than Chloroquine and it gives almost the same values of the score (-5.7853 Kcal/mol and -6.4530 Kcal/mol respectively) therefore we can consider that the two complexes 6vw1-Isothymol and 6vw1-chloroquine are stables with higher binding affinity. According to these docking results we can classify Isothymol as the good inhibitor of the enzyme ACE2 compared to the all ligands studied.

3.2.. *In silico* evaluation of druglikness, ADME/toxicity properties and PASS prediction {#s0011}
-----------------------------------------------------------------------------------------

This test is performed to facilitate the creation of new drug molecules, the molecules of which must comply with the conditions of the following five Lipinski's rule: molecular weight: ≤ 500, number of hydrogen bond donors: ≤ 5, number of hydrogen bond acceptors: ≤ 10, lipophilicity (expressed in LogP): ≤5 and molar refractivity from 40 to 130 (Lipinski et al., [@CIT0036]). The results of this study are shown in the [Table 4](#t0004){ref-type="table"}.

###### 

List of the results of the ligands druglikeness properties.

  Drug Likeness Properties       Chloroquine   Isothymol   beta-D-Mannose   Captopril   Thymol   limonene   p-cymene   γ-terpinene
  ------------------------------ ------------- ----------- ---------------- ----------- -------- ---------- ---------- -------------
  Molecular weight g/mol         319.87        220.31      180.16           217.29      150.22   136.23     134.22     136.23
  Concensus Log *P*o/w           4.15          3.85        −2.62            0.62        2.84     3.36       3.19       3.05
  Log S                          −4.06         −3.56       0.25             −1.71       −2.54    −2.54      −2.83      −2.37
  Num. H-bond acceptors          2             2           6                3           1        0          0          0
  Num. H-bond donors             1             0           5                1           1        0          0          0
  Molar Refractivity             97.41         67.10       35.74            59.97       48.01    47.12      45.99      47.12
  Lipinski                       Yes           Yes         Yes              Yes         Yes      Yes        Yes        Yes
  Ghose                          Yes           Yes         No               Yes         No       No         No         No
  Veber                          Yes           Yes         Yes              Yes         Yes      Yes        Yes        Yes
  Egan                           Yes           Yes         Yes              Yes         Yes      Yes        Yes        Yes
  Muegge                         Yes           Yes         No               Yes         No       No         No         No
  Bioavailability score          0.55          0.55        0.55             0.56        0.55     0.55       0.55       0.55
  Synthetic accessibility (SA)   2.76          1.96        4.08             2.47        1.00     3.46       1.00       3.11
  TPSA (Å²)                      28.16         26.30       110.38           96.41       20.23    0.00       0.00 Å²    0.00
  No of rotatable bonds          8             4           1                4           1        1          1          1
  Druglikeness score             7.39          −1.37       −3.78            −0.96       −3.02    −21.85     −5.63      −2.82
  Drug-Score                     0.30          0.31        0.51             0.63        0.18     0.06       0.22       0.29
  Solubility                     −4.06         −3.56       0.25             −1.71       −2.54    −2.54      −2.83      −2.37
  Reproductive effective         Yes           Yes         Yes              Yes         No       No         Yes        Yes
  irritant                       No            No          Yes              Yes         Yes      No         No         No
  Tumorigenic                    Yes           Yes         Yes              Yes         Yes      No         No         Yes
  Mutagenic                      No            Yes         Yes              Yes         No       No         Yes        Yes

Chloroquine, Isothymol, β-D- Mannose, Captopril, Thymol, Limonene, P-Cymene and γ-Terpinene have respectively the following molecular weights: (319.87, 220.31, 180.16, 217.29, 150.22, 136.23, 134.22, 136.23) g/mol, they have all a molecular weight ≤ 500 g/mol, and also respectively present the following values of the topological polar surface (TPSA) (28.16, 26.30, 110 .38, 96.41, 20.23, 0.00, 0.00, 0.00) Å2. The lowest TPSA values always give good results, so we note that the molecules from the plant *Ammoides verticillata* are better behaved than the co-crystallized ligand and Captopril drug. By comparing the lipophilicity (LogP) values of our ligands series, we observe that they all have values less than 5 so they have shown very good results and can be easily absorbed in the body.

However, the LogS solubility values of the ligands tested are between -4.06 and 0.25. The Isotymol and chloroquine having the lowest values and β-D- Mannose having the greatest value, the lowest values of which are always appreciable. However all the ligands have a number of hydrogen bonding donors: ≤ 5, a number of hydrogen bonding acceptors: ≤ 10 and also reactivity values between 35.75 and 130. So we can say that the five Lipinski's rule was verified for the ligands from the plant *Ammoides verticillata*. Veber's rule which represents the oral bioavailability of a possible drug molecule; it is verified for all the list of ligands studied.

We also note that another Egan's rule which defines the absorption of the drug molecule is verified for all ligands, on the other hand the 2 rules of Ghose's and Muegge's (Ghose et al., [@CIT0020]; Veber et al., [@CIT0059]; Egan et al., [@CIT0016]; Muegge et al., [@CIT0040]) are verified only for chloroquine drug and Isothymol therefore which means that Isothymol can be considered as a good drug. The ease of synthesizing a drug is given by the Synthetic Accessibility Score (SA). The molecule which gives a score 1 is easy to synthesize it, on the other hand the score 10 represents a difficulty of synthesis therefore according to our results the molecule Isothymol is easier to synthesize it by contribution to the Chloroquine drug. We also notice that some ligands gives the reproductive effects, the irritant, Tumorigenic, Mutagenic properties and all the ligands from the plant *Ammoides verticillata* showed a bioavailability score of 0.55, and also good values of Druglikness score, Solubility values and drug score. As conclusion the Isothymol which represents the highest yield in the plant *Ammoides verticillata* has followed the Lipinski's, Veber's, Egan's, Ghose's and Muegge's rules, it also has an 1.96 SA value so it is easy to synthesize it and it can to be considered as successful drug.

The results of the ADME tests are listed in the [Table 5](#t0005){ref-type="table"} these tests were carried out to determine the pharmacological and pharmacodynamic properties of a drug in the biological system.

###### 

The ADME/T test results of ligands (various pharmacokinetic and pharmacodynamic properties).

  Class                               Properties               Chloroquine         Isothymol          beta-D-Mannose   Captopril       Thymol          limonene        p-cymene        γ-terpinene
  ----------------------------------- ------------------------ ------------------- ------------------ ---------------- --------------- --------------- --------------- --------------- ---------------
  **Absorption**                      Caco-2 permeability      Optimal             Optimal            Low              Optimal         Optimal         Optimal         Optimal         Optimal
  Pgp-inhibitor                       Non-inhibitor            Inhibitor           Non-inhibitor      Non-inhibitor    Non-inhibitor   Non-inhibitor   Non-inhibitor   Non-inhibitor   
  Pgp-substrate                       substrate                Non-substrate       Non-substrate      Non-substrate    Non-substrate   Non-substrate   Non-substrate   Non-substrate   
  Human Intestinal Absorption (HIA)   HIA positive             HIA positive        HIA negative       HIA positive     HIA positive    HIA positive    HIA positive    HIA positive    
  **Distribution**                    Plasma Protein Binding   Good                Good               Low              Low             Good            Good            Low             Low
  BBB (Blood--Brain Barrier)          BBB positive             BBB positive        BBB positive       BBB negative     BBB positive    BBB positive    BBB positive    BBB positive    
  **Metabolism**                      CYP450 1A2 inhibitor     Non-inhibitor       Inhibitor          Non-inhibitor    Non-inhibitor   Inhibitor       Non-inhibitor   Non-inhibitor   Non-inhibitor
  CYP450 1A2 substrate                Substrate                Substrate           Non-substrate      Non-substrate    Substrate       Substrate       Substrate       Substrate       
  CYP450 3A4 inhibitor                Non-inhibitor            Non-inhibitor       Non-inhibitor      Non-inhibitor    Non-inhibitor   Non-inhibitor   Non-inhibitor   Non-inhibitor   
  CYP450 3A4 substrate                Substrate                Substrate           Non-substrate      Non-substrate    Non-substrate   Substrate       Non-substrate   Non-substrate   
  CYP450 2C9 inhibitor                Non-inhibitor            Inhibitor           Non-inhibitor      Non-inhibitor    Non-inhibitor   Non-inhibitor   Non-inhibitor   Non-inhibitor   
  CYP450 2C9 substrate                Non-substrate            Non-substrate       Non-substrate      Non-substrate    Substrate       Substrate       Substrate       Substrate       
  CYP450 2C19 inhibitor               Non-inhibitor            Inhibitor           Non-inhibitor      Non-inhibitor    Inhibitor       Non-inhibitor   Non-inhibitor   Non-inhibitor   
  CYP450 2C19 substrate               Substrate                Substrate           Non-substrate      Non-substrate    Substrate       Substrate       Substrate       Substrate       
  CYP450 2D6 inhibitor                Inhibitor                Non-inhibitor       Non-inhibitor      Non-inhibitor    Non-inhibitor   Non-inhibitor   Non-inhibitor   Non-inhibitor   
  CYP450 2D6 substrate                Substrate                Substrate           Non-substrate      Substrate        Substrate       Substrate       Substrate       Substrate       
  **Excretion**                       T1/2 (h)                 2.23                1.225              1.129            0.793           1.313           1.741           1.772           1.78
  **Toxicity**                        hERG (hERG Blockers)     **Blockers**        **Non-blockers**   Non-blockers     Non-blockers    Non-blockers    Non-blockers    Non-blockers    Non-blockers
  H-HT (Human Hepatotoxicity)         HHT positive             HHT negative        HHT positive       HHT positive     H-HT negative   H-HT negative   HHT negative    H-HT negative   
  Ames (Ames Mutagenicity)            **Ames positive**        **Ames negative**   Ames negative      Ames negative    Ames negative   Ames negative   Ames negative   Ames negative   
  DILI (Drug Induced Liver Injury)    DILI negative            DILI negative       DILI negative      DILI negative    DILI negative   DILI negative   DILI negative   DILI negative   

In the Absorption part, Isothymol, Thymol, Limonene, P-Cymene, γ-Terpinene, Chloroquine and Captopril present at optimal Caco-2 permeability except β-D- Mannose at low Caco-2 permeability. This test is done to check whether the drug will be easily absorbed in the intestine or not. However Isothymol, Thymol, Limonene, P-Cymene, γ-Terpinene, Chloroquine and Captopril show a positive HIA test so they will be well absorbed by the human intestine. The inhibition of the Pgp glycoprotein facilitates the transport of many drugs inside the cell, according to our results Isothymol is the only pgp inhibitor so it will be easily absorbed by the cells. Furthermore in the distribution part, the binding of drugs to plasma proteins is also an important pharmacological parameter; in our study the Captopril drug give a low capacity and negative test but Chloroquine drug and Isothymol show a good capacity and positive test for binding to plasma proteins so they are able to cross the blood-brain barrier. Also in the metabolism part, the cytochrome P450 is an enzyme family which metabolizes the drugs, so in our test only Isothymol is the inhibitor of CYP 450 A2, CYP4502C9, CYP4502C19, and also the substrate of CYP450A2, CYP4593A4, CYP4502C19, CYP4502D6, so the Isothymol can be metabolized by these enzymes . In the excretion part, the half-life of a drug describes the time required for the amount of a drug to be reduced in the body by half or 50% (Swierczewska et al., [@CIT0056]; Smalling, [@CIT0054]; Sahin & Benet, [@CIT0047]). The series of ligands studied have a half-life between 1.129 h and 2.23 h of which the Isothymol ligand of the plant *Ammoides verticillata* has a significant half-life. That is to say, they give a potential effectiveness.

Regarding the toxicity part, HERG is a K + channel found in the heart muscle and ensures the correct rhythm of the heart, if HERG is blocked by certain drugs, it can cause cardiac arrhythmia and death (Sanguinetti et al., [@CIT0049]; Aronov, [@CIT0003]), the Chloroquine drug which is used for the treatment of COVID-19 is blocker to HERG so it can cause cardiac arrhythmia and death but the Isothymol is not HERG blocker which gives good result as drug. For the H-HT, AMES, Chloroquine drug gives the positive test but Isothymol present negative tests in the toxicity part, and all the molecules derived from the *Ammoides verticillata* present negative tests. In this ADMET part it can be suggested that the Isothymol molecule has better drug properties than the Chloroquine drug.

Prediction tests were also carried out for 10 biological activities, the results of which are in the [Table 6](#t0006){ref-type="table"}. We note that all the ligands show some biological activities among the 10 tested.

###### 

The PASS prediction results of the biological activities of the ligands series.

  Sl no   Biological activities             Chloroquine   Isothymol   beta-D-Mannose   Captopril   Thymol   limonene   p-cymene   γ-terpinene                                                           
  ------- --------------------------------- ------------- ----------- ---------------- ----------- -------- ---------- ---------- ------------- ------- ------- ------- ------- ------- ------- ------- -------
  01      Membrane integrity agonist        0,279         0,210       0,737            0,011       0,844    0,005      --         --            0,802   0,036   0,375   0,151   0,745   0,047   --      --
  02      HMOX1 expression enhancer         --            --          0,335            0,079       0,383    0,064      --         --            0,635   0,015   0,391   0,062   0,509   0,034   0,368   0,068
  03      Chlordecone reductase inhibitor   --            --          0,610            0,059       --       --         --         --            0,784   0,023   0,582   0,065   0,769   0,026   0,643   0,052
  04      HIF1A expression inhibitor        --            --          0,534            0,047       0,514    0,053      --         --            0,808   0,011   --      --      0,815   0,011   --      --
  05      Histidine kinase inhibitor        --            --          0,251            0,161       0,297    0,105      --         --            0,373   0,062   --      --      --      --      --      --
  06      Aldehyde oxidase inhibitor        0,797         0,009       --               --          --       --         0,386      0,069         0,603   0,032   --      --      0,492   0,051   0,300   0,094
  07      Antimutagenic                     --            --          --               --          --       --         --         --            --      --      0,209   0,073   --      --      --      --
  08      Mucomembranous protector          --            --          0,917            0,004       --       --         0,766      0,029         0,922   0,004   --      --      0,919   0,004   0,789   0,021
  09      TP53 expression enhancer          --            --          0,479            0,100       0,765    0,015      --         --            0,592   0,052   0,627   0,042   0,541   0,071   --      --
  10      Chemopreventive                   --            --          0,305            0,036       0,573    0,011      --         --            0,360   0,027   --      --      0,234   0,054   --      --

[Table 7](#t0007){ref-type="table"} shows five toxic effects (Lagunin et al., [@CIT0033]) tested for all the ligands of which it is noted that Chloroquine and captopril drugs presents the active Immunotoxicity test but Isothymol is inactive for the five toxic effects. However, according to [Table 6](#t0006){ref-type="table"}, all the ligands Isothymol, Chloroquine and Captopril belong to toxicity class 4 with (300 \<LD50 ≤ 2000), so they would be harmful if swallowed.

###### 

The PASS prediction results showing the adverse and toxic effects of the ligands series.

  Sl no   Target                                 Chloroquine   Isothymol    beta-D-Mannose   Captopril   Thymol   limonene   p-cymene   γ-terpinene                                                                
  ------- -------------------------------------- ------------- ------------ ---------------- ----------- -------- ---------- ---------- ------------- ------ ---------- ------ ---------- ------ ---------- ------ ----------
  01      Immunotoxicity                         0.96          **Active**   0.89             Inactive    0.96     Active     0.96       **Active**    0.93   Inactive   0.96   Active     0.96   Active     0.96   Active
  02      Cytotoxicity                           0.93          Inactive     0.70             Inactive    0.93     Inactive   0.93       Inactive      0.89   Inactive   0.93   Inactive   0.93   Inactive   0.93   Inactive
  03      Mutagenicity                           0.97          Inactive     0.84             Inactive    0.97     Inactive   0.97       Inactive      0.99   Inactive   0.97   Inactive   0.97   Inactive   0.97   Inactive
  04      Carcinogenicity                        0.62          Inactive     0.62             Inactive    0.62     Inactive   0.62       Inactive      0.60   Inactive   0.62   Inactive   0.62   Inactive   0.62   Inactive
  05      Phosphoprotein (Tumor Supressor) p53   0.96          Inactive     0.97             Inactive    0.96     Inactive   0.96       Inactive      0.96   Inactive   0.96   Inactive   0.96   Inactive   0.96   Inactive

The possible sites of metabolism by CYPs 1A2, 2A6, 2B6, 2C19, 2C8, 2C9, 2D6, 2E1 and 3A4 of Isothymol are illustrated in [Table 8](#t0008){ref-type="table"}. The possible sites of a chemical compound, where the metabolism by the isoforms of CYP450 enzymes may be taken place, are indicated by circles on the chemical structure of the molecule **(**Zaretzki et al., [@CIT0061]). The P450 SOM predictions showed that Isothymol had 5 sites of metabolism (SOMs) for the CYP 450 2B6 enzyme, 4 sites for CYP 450 2A6, CYP 4502C8, CYP 450 2D6, and 3sites for CYP 4501A2, CYP 450 2C9, CYP 450 2C19 and CYP 450 2E1 .

###### 

List of the P450 sites of metabolism prediction study of the ligands molecules.

  Drug Likeness Properties   Isothymol
  -------------------------- -----------------------------------
  **1A2**                    ![](TBSD_A_1763199_ILG0017_C.gif)
  **2A6**                    ![](TBSD_A_1763199_ILG0018_C.gif)
  **2B6**                    ![](TBSD_A_1763199_ILG0019_C.gif)
  **2C8**                    ![](TBSD_A_1763199_ILG0020_C.gif)
  **2C9**                    ![](TBSD_A_1763199_ILG0021_C.gif)
  **2C19**                   ![](TBSD_A_1763199_ILG0022_C.gif)
  **2D6**                    ![](TBSD_A_1763199_ILG0023_C.gif)
  **2E1**                    ![](TBSD_A_1763199_ILG0024_C.gif)
  **3A4**                    ![](TBSD_A_1763199_ILG0025_C.gif)

3.3.. Target prediction {#s0012}
-----------------------

Molecular Target studies are important to find the phenotypical side effects or potential cross reactivity caused by the action of Isothymol the best ligand. The top 25 results are given in the [Figure 6](#F0006){ref-type="fig"}. The possible sites of target which the compound may bind to are mostly the targets of protease and oxidoreductase which stimulate the drug reaction accordingly.

![Top-25 of Target Predicted for Isothymol.](TBSD_A_1763199_F0006_C){#F0006}

![Pharmacophore Mapping of Isothymol. Here, cyan color- hydrogen bond acceptor, orange color-aromatic, green color-hydrophobic.](TBSD_A_1763199_F0007_C){#F0007}

3.4.. Pharmacophore mapping {#s0013}
---------------------------

The Pharmacophore Mapping is carried for the Isothymol best ligand of the *Ammoides Verticilata*. Isothymol showed 2 hydrogen acceptor bonds, 6 Hydrophobic groups and 3 Aromatic rings. It also generated a good number of good contacts with the Pharmacophore of ACE2 [Figure 7](#F0007){ref-type="fig"}. The Pharmacophore of Isothymol generates a hypothesis which can be used successfully in biological screening for further experiments (Dixon et al., [@CIT0014]).

3.5.. Molecular dynamics simulation {#s0014}
-----------------------------------

The Molecular Dynamics Simulation results are showed in the [Figure 8](#F0008){ref-type="fig"}.

![Results of molecular dynamics simulation of Isothymol-ACE2 Receptor. (a) NMA mobility, (b) deformability, (c) B-factor, (d) eigenvalues, (e) variance (red color indicates individual variances and green color indicates cumulative variances), (f) co-variance map (correlated (red), uncorrelated (white) or anti-correlated (blue) motions) and (g) elastic network (darker gray regions indicate more stiffer regions) of the complex.](TBSD_A_1763199_F0008_C){#F0008}

[Figure 8a](#F0008){ref-type="fig"} illustrates the normal mode analysis (NMA) of Isothymol-ACE2 complex. The deformability graph of the complex illustrates the peak in the graphs correspond to the regions in the protein with deformability [Figure 8b](#F0008){ref-type="fig"}. The B-factor graph of the complex gives easy visualization and understanding of the comparison between the NMA and the PDB field of the complex [Figure 8c](#F0008){ref-type="fig"}. The eigenvalue of the complex is illustrated in [Figure 8d](#F0008){ref-type="fig"}. The docked complex generated eigenvalue of 1.408491e-06. The variance graph indicates the individual variance by red colored bars and cumulative variance by green colored bars [Figure 8e](#F0008){ref-type="fig"}. [Figure 8f](#F0008){ref-type="fig"} illustrates the co-variance map of the complexes where the correlated motion between a pair of residues is indicated by red color, uncorrelated motion is indicated by white color and anti-correlated motion is indicated by blue color. The elastic map of the complex shows the connection between the atoms and darker gray regions indicate stiffer regions [Figure 8g](#F0008){ref-type="fig"}.

From the molecular dynamics study of Isothymol-ACE2 docked complex, it is clear that the complex had a very good amount of deformability [Figure 8b](#F0008){ref-type="fig"} as well as it had low eigenvalue of 1.408491e-06, for this reason, this lower eigenvalue, represent the easier the deformability of the complex [Figure 8d](#F0008){ref-type="fig"} and also represents the motion stiffness of the protein complex.

However, the variance map showed high degree of cumulative variances than individual variances [Figure 8e](#F0008){ref-type="fig"}. The co-variance and elastic network map also produced satisfactory results [Figure 8f and 8g](#F0008){ref-type="fig"}.

*In vivo* studies have shown that the therapeutic qualities of *Ammoids verticillata* are known to be the oldest in local folk medicine. Indeed, Ibn El Beithar, in his treatise on the simple, in the article Athrilal indicates that this plant was used in the treatment of leprosy by a section of the tribe of Oudjeham, near Bougie in 1220 (Trabut, [@CIT0058]). It also has major antibacterial activity with a broad spectrum of action, antifungal (Dubey & Mishra, [@CIT0015]; Grosjean, [@CIT0021]), antiviral (Grosjean, [@CIT0021]), it is used for the treatment of cholera (Avesina, [@CIT0004]; Schirner, [@CIT0051]), asthma (Avesina, [@CIT0004]; Boskabady & Shaikhi, [@CIT0010]; Schirner, [@CIT0051]), fever, typohoid fever and bronchopulmonary diseases (Bekhechi, [@CIT0006]). Thymol and Isothymol molecules from this plant are also widely used in cough medicine, throat irritation and cholera (Bhargava et al., [@CIT0008]; Joshi et al., [@CIT0030]).

In our study and after the best results obtained for the Isothymol ligand of *Ammoides verticilata* it can be used as potential agents to treat COVID-19 if we compared with Choloroquine and it emerged as the most potent anti-ACE2 agent.

4.. Conclusion {#s0015}
==============

The aim of our study is to investigate the potent of new natural's compounds such as Isothymol, Thymol, Limonene, P-Cymene and γ-Terpinene from *Ammoides verticillata* plant as inhibitors for ACE2 target. These compounds are tested *in silico* study for the inhibition to this enzyme. Molecular docking used to study interaction between new compounds and ACE2 with score energy investigation and druglikeness properties experiments, ADME/T tests, PASS prediction, the P450 Site of Metabolism (SOM), the Molecular Target, Phamacophore Mapping, Molecular dynamics simulation have been performed to verify *in silico* the drug properties of the best ligand.

The top ligand Isothymol which is the major component (51.2%), in *Ammoides verticillata* has high binding affinity (Score) and one almost stable interaction with ACE2 target.

Our study showed for these natural components quite similar and very good results in all the aspects into account. Hence, Isothymol can be further developed as drug candidates against ACE2 receptor of coronaviruses, notably that responsible for severe acute respiratory syndrome. Finally we can suggest from this *in silico* study that *Ammoides verticillata* (Desf.) Briq. essential oils components can blocks the receptor ACE2 and could make it more difficult for coronavirus to enter cells, which could at least significantly slow the epidemic until the virus disappears. Though these properties are appreciable *in silico*, further studies of *in vitro* and clinical studies dealing with SARS-CoV-2 should be considered for further studies.
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